### (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 19 May 2005 (19.05.2005)

**PCT** 

# (10) International Publication Number WO 2005/045001 A3

(51) International Patent Classification<sup>7</sup>: C12N 5/00, 5/02, 5/06, 5/08, 5/10 C12P 21/04,

(21) International Application Number:

PCT/US2004/004681

(22) International Filing Date: 17 February 2004 (17.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/447,684

14 February 2003 (14.02.2003) US

- (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; 1705 El Camino Real, Palo Alto, CA 94306-1106 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HORI, Yuichi [JP/JP]; 6-14-C505, Minatojima-nakamachi, Chuo-ku, Kobe 650-0046 (JP). KIM, Seung [US/US]; 817 Pine Hill Road, Stanford, CA 94305 (US).
- (74) Agents: VINCENT, Matthew, P. et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
  4 August 2005


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INSULIN-PRODUCING CELLS DERIVED FROM STEM CELLS



(57) Abstract: The disclosure provides, among other things, insulin-producing cells derived from stem cells, such as human stem cells and neural stem cells. The disclosure discloses a relationship between caudalizing factors and the differentiation of insulin-producing cells.





International application No.

PCT/US04/04681

A CL	ASSIFICATION OF SUBJECT MATTER						
PC(7) : C12P 21/04; C12N 5/00, 5/02, 5/06, 5/08, 5/10							
1 03 CL : 433/0.1.325.357 363 366 369							
According to International Patent Classification (IPC) or to both national classification and IPC  B. FIELDS SEARCHED							
	2. Third scale in						
IIS - 2	Minimum documentation searched (classification system followed by classification symbols)  U.S.: 435770 1 325 353 366 369						
0.5	U.S.: 435/70.1, 325, 352, 363, 366, 368						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic data base consulted during the international and the consulted during the consulted during the international and the consulted during the c							
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  Please See Continuation Sheet							
C. DOC	UMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document with in 1:						
X	Citation of document, with indication, where	appropriate	e, of the relevant passages	Relevant to claim No.			
	ZULEWSKI, H. BT AL. Multipotential Nestin-Por Pancreatic Islets Differentiate Ex Vivo Into Pancre Phenotypes March 2001, Vol. 50, No. 2	stive Stem (	Cells Isolated From Adult	1-9			
	Phenotypes. March 2001, Vol. 50, No. 3, pages 52	1-533 see l	Figure 4				
A	LECHNER, A. ET AL. Nestin-Postive Progenitor Cells Derived from Adult Human Pancreatic Islets of Langerhans Contain Side Population (SP) Cells Defined by Expression of the ABCG2 (RCRP1) ATP-hinding Contact. The contact of the ABCG2 (RCRP1) ATP-hinding Contact of the ABCG2 (RCRP1) AT						
	Research Communications 03 May 2002, Vol. 293	, No. 2, pag	es 670-674, entire document.				
Α	BANI-YAGHOUB, M. ET AL. Insulin Acts as a M. Stem Cells with Multilineage Differentiation But	Ivoqenia Di	Stranger Line 1				
		itial. Develo	onment Sentember 2004 34-1	1-9			
	131, No. 17, pages 4287-4298, entire document.		opinion september 2004, Vol.				
Α	DIIDNIS CI DE AT MI						
Α.	BURNS, C.J. ET AL. The in vitro differentation of	rat neural s	stem cells into an insulin-	1-9			
	expressing phenotype. Biochemical and Biophysica 2005, Vol. 326, No. 3, pages 570-577, entire documents.	I Parasah i	Communications 21 January				
[	, and the state of	nent.		,			
A	CHOI, Y. ET AL. Adult Pancreas Generates Multir	notent Stem	Cells and Dansand				
	CHOI, Y. ET AL. Adult Pancreas Generates Multipotent Stem Cells and Pancreatic and Nonpancreatic Progeny. Stem Cells 2004, Vol. 22, No. 6, pages 1070-1084, entire						
M - '			- Control Control				
Further	documents are listed in the continuation of Box C.		See patent family annex.				
* Sp	ecial categories of cited documents:	"T"	later document published after the inten	W. ICH			
"A" document	defining the general state of the art which is not considered to be of						
F	1227111200		p-mopro or theory underlying the invent	ion			
"E" earlier app	er application or patent published on or after the international filing date  "X"  document of particular relevance; the considered novel or cannot be consi		document of particular relevance; the cle considered novel or cannot be considere when the document in taken of care	aimed invention cannot be			
"L" document which may throw doubte on priority desired.			when the document is taken alone	a to mvoive an inventive step			
specified)	te publication date of another citation or other special reason (as	"Y"	document of particular relevance; the cla	airred invention cannot be			
"O" document	referring to un and disclasses		considered to involve an inventive step with one or more other such documents,	then the demonstrate and			
	referring to an oral disclosure, use, exhibition or other means		obvious to a person skilled in the art	such combination being			
priority dat	published prior to the international filing date but later than the eclaimed	"&"	document member of the same patent fan	nilv			
Date of the act	nual completion of the international search	<del>,</del>					
		Date of m	nailing of the international search	report			
5 March 2005 (15.03.2005)			0 0 10 W 7002				
Mail our arms	ling address of the ISA/US Stop PCT, Atm: ISA/US	Apthprize		,			
Commissioner for Patents			Christopher J. Nichols, Ph.D.				
P.O. Box 1450							
Facsimile No. (703) 305-3230  Telephone No. (571) 272-1600							
m PCT/ISA/210 (second sheet) (January 2004)							

International application No. PCT/US04/04681

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEABERG, R. M. ET AL. Clonal Identification of Multipotent Precursors from Adult Mouse Pancreas that Generate Neural and Pancreatic Lineages. Nature Biotechnology September 2004, Vol. 22, No. 9, pages 1115-1124.	1-9
	-	
	·	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

International application No.

PCT/US04/04681 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet) Box No. II This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: 2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Observations where unity of invention is lacking (Continuation of item 3 of first sheet) Box No. III This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-9

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(2)) (January 2004)

Remark on Protest

International application No. PCT/US04/04681

### BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-9, drawn to an insulin-producing cell.

Group 2, claim(s) 10-16, drawn to a method for making a cell composition comprising cells that are receptive to treatment with an islet cell differentiation factor.

Group 3, claim(s) 17-23, drawn to a method for making insulin-producing cells comprising culturing neural or neuroendocrine stem cells in at least two different media.

Group 4, claim(s) 24-25, drawn to a method for assessing a test agent.

Group 5, claim(s) 26, drawn to a therapeutic cell composition.

Group 6, claim(s) 27-30 and 45-53, drawn to a method of ameliorating a condition related to insufficient pancreatic function.

Group 7, claim(s) 31, drawn to a non-human animal.

Group 8, claim(s) 32-35, drawn to a method for testing the developmental potential of a cell of interest.

Group 9, claim(s) 36-38, drawn to a method for predicting the ability of an affinity reagent to bind to a pancreatic progenitor cell.

Group 10, claim(s) 39-44, drawn to a method for making human insulin producing cells.

According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups 1-10 do not relate to a single general inventive concept because they lack the same or corresponding special technical feature. The technical feature of Group 1 is an insulin producing cell which is shown by ZULEWSKI et al. Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes. Diabetes March 2001, Vol. 50, No. 3, pages 521-533. ZULEWSKI et al. teaches a nestin-positive insulin producing cell culture thus the special technical feature of claim 1 lacks novelty and does not make it a contribution over the prior art (see Figure 4).

Group 1 is drawn to the special technical feature of an insulin-producing cell, which is not required by any of the other groups.

Group 2 is drawn to the special technical feature of cells that are receptive to treatment with an islet cell differentiation factor, which is not required by any of the other groups.

International'application No. PCT/US04/04681

Group 3 is drawn to the special technical feature of culturing neural or neuroendocrine stem cells in at least two different media, which is not required by any of the other groups.

Group 4 is drawn to the special technical feature of test agent, which is not required by any of the other groups.

Group 5 is drawn to the special technical feature of therapeutic cell composition, which is not required by any of the other groups.

Group 6 is drawn to the special technical feature of method of ameliorating a condition related to insufficient pancreatic function, which is not required by any of the other groups.

Group 7 is drawn to the special technical feature of a non-human animal, which is not required by any of the other groups.

Group 8 is drawn to the special technical feature of testing the developmental potential of a cell of interest, which is not required by any of the other groups.

Group 9 is drawn to the special technical feature of a method for predicting the ability of an affinity reagent, which is not required by any of the other groups.

Group 10 is drawn to the special technical feature of a method for making human insulin producing cells, which is not required by any of the other groups.

Continuation of B. FIELDS SEARCHED Item 3: WEST (USPT, PGPUBS, US OCR, JPO, EPO, DERWENT); STN (BIOSCIENCE); NCBI (PUBMED) neural, neuroendocrine, stem cell, insulin, pancreas, nestin, glucagon, somtatostatin, precursor cell, multipotent cell